Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jul 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Trigeminal Brainstem Mapping 2," is studying how different parts of the brain respond to stimulation of the trigeminal nerve, which is often involved in migraine disorders. Researchers want to learn more about how the brain processes pain signals and other sensations related to this nerve by using advanced imaging techniques. They will scan the entire brain, brainstem, and upper spinal cord while participants experience both painful and non-painful electrical stimulation of the trigeminal nerve and the arm as a comparison.
To participate in this study, you need to be healthy and able to undergo an MRI scan. Unfortunately, individuals with headache disorders, psychological conditions, or who are pregnant cannot take part. If eligible, participants can expect to undergo brain scans while receiving safe electrical stimulation, helping researchers gain valuable insights into the mechanisms of migraine and related conditions. This study is currently recruiting participants aged between 18 and 65.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy
- • suitable fo MRI
- Exclusion Criteria:
- • headache disease
- • psychological disorder
- • pregnancy
- • all exclusion criteria necessary for imaging in a 3 T MRI scanner
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported